Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Peter HillmenBarbara EichhorstJennifer R BrownNicole LamannaSusan M O'BrienConstantine S TamLugui QiuMaciej KazmierczakKeshu ZhouMartin SimkovicJiří MayerAmanda Gillespie-TwardyMazyar ShadmanAlessandra FerrajoliPeter S GanlyRobert WeinkoveSebastian GrosickiAndrzej MitalTadeusz RobakAnders ÖsterborgHabte A YimerTommi SalmiMeng JiJessica YeciesAdam IdoineKenneth WuJane HuangWojciech JurczakPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Zanubrutinib had a significantly higher ORR, lower atrial fibrillation rate, and improved progression-free survival and overall cardiac safety profile versus ibrutinib. These data support improved efficacy/safety outcomes with selective BTK inhibition.
Keyphrases
- chronic lymphocytic leukemia
- phase iii
- free survival
- open label
- clinical trial
- atrial fibrillation
- diffuse large b cell lymphoma
- phase ii
- double blind
- acute myeloid leukemia
- placebo controlled
- tyrosine kinase
- heart failure
- multiple myeloma
- left ventricular
- type diabetes
- direct oral anticoagulants
- coronary artery disease
- catheter ablation
- acute coronary syndrome
- mitral valve
- metabolic syndrome
- left atrial
- deep learning
- skeletal muscle
- venous thromboembolism